BioInquire Awarded Phase II STTR by NIH for Clinical Proteomics Software Development

BioInquire Awarded Phase II STTR by NIH for Clinical Proteomics Software Development

Athens, GA, October 01, 2009 --(PR.com)-- BioInquire, LLC today announced the award of a Phase II Small Business Technology Transfer (STTR) grant totaling $747,000. The grant, entitled Development of Software for Comparative and Quantitative Clinical Proteomics, was awarded by the National Institute of Health.

Specifically, the two year program supports the continued development of BioInquire's proteomics software suite, ProteoIQ. The primary objective of the program is to create a fully integrated software platform that is particularly well suited for large clinical proteomic studies.

"While software applications exist for validation and quantitation of MS/MS data, no current product adequately addresses the needs of researchers doing large scale clinical proteomics," said James Atwood, co-founder and CEO of BioInquire. "The award will allow us to bridge that technology gap by providing a software solution that will enable the comparison of proteomic data across hundreds of patients. Our goal is to serve as a critical link between the initial analyses of raw MS data to the realization of meaningful discovery."

The original program was started with a Phase I STTR in January of 2008, and BioInquire announced the commercial release of ProteoIQ in June of 2008.

"ProteoIQ combines label-free or reporter ion quantification with data mining functions to assist researchers in finding differences between multiple proteomic data sets," said Brent Weatherly, co-founder and CTO of BioInquire. "We are particularly excited about the future developments in ProteoIQ, as it represents an integral part of BioInquire's mission to provide software that fuels the scientific discovery process."

About BioInquire, LLC
BioInquire, LLC (www.bioinquire.com) is an Athens, GA based bioinformatics company that provides innovative solutions to the life science industry. BioInquire's primary product, ProteoIQ, is designed and distributed for use in academic, pharmaceutical, biotechnology, and molecular diagnostic laboratories that utilize MS/MS proteomics research techniques.

Suggested Articles

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.